Study links low-level arsenic exposure in water to diabetes
21 Aug 2008

Low-level exposure to arsenic in drinking water seems to be associated with an increased prevalence of type 2 diabetes, according to a new study.

Published in the August 20th issue of the journal of the American Medical Association, the research by staff from the Johns Hopkins Bloomberg School of Public Health in Maryland, USA involved the study of a total of 788 adults aged 20 or above.

The participants had their urine tested for levels of the odourless, tasteless and colourless substance as part of a government-conducted 2003-4 survey.

It was found that 7.7 per cent of the subjects who had type 2 diabetes - after adjusting for other risk factors - had a 26 per cent higher level of arsenic in their urine than those without the condition.

Some 20 per cent of the participants who had the highest levels of arsenic in their urine (16.5 micrograms per litre) had 3.6 time higher risk of having the condition than the fifth with the lowest level (three micrograms per litre).

"Given widespread exposure to inorganic arsenic from drinking water worldwide, elucidating the contribution of arsenic to the diabetes epidemic is a public health research priority with potential implications for the prevention and control of diabetes," the researchers stated.

Login and visit the Diabetes Knowledge Centre

Print Article    Bookmark

• Porridge could limit type-2 diabetes side effects 09/01/09
• Men with type-2 diabetes at greater risk of cardiovascular death 06/01/09
• Decline in mental processing affects diabetes patients, study reveals 05/01/09
• Leptin study could lead to new diabetes treatment 23/12/08
• Symptomless virus linked with type 1 diabetes 19/12/08

• PRANDIN Tablets - 49.44%
  ... in patients with Type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in Type 2 diabetes patients who are not ...
  
  
• DDAVP - 49.42%
  ... and treatment of vasopressin-sensitive cranial diabetes insipidus; establishing renal concentration capacity. DDAVP Tablets: Treatment of vasopressin-sensitive cranial diabetes insipidus; treatment of post-hypophysectomy polyuria/ polydipsia. DDAVP/Desmopressin Injection: Cranial diabetes insipidus ...
  
  
• JANUVIA Film-Coated Tablets - 47.95%
  JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin when diet and exercise, plus metformin do not provide adequate glycaemic control. For patients with type 2 diabetes mellitus in whom use of a PPAR? agonist (i.e. a ...
  
  
• EXUBERA - 47.95%
  ... for the treatment of adult patients with type 2 diabetes mellitus not adequately controlled with oral antidiabetic agents and requiring insulin therapy. EXUBERA is also indicated for the treatment of adult patients with type 1 diabetes mellitus, in addition to long or intermediate acting ...
  
  
• NOCUTIL - 47.95%
  Treatment of idiopathic central diabetes insipidus, or diabetes insipidus occurring after hypophysectomy, cranial trauma, or surgery in the pituitary region ...
  
  
• GLUCOPHAGE - 47.95%
  Non-insulin dependent (type II) diabetes either alone or with sulphonylureas. Adjuvant therapy in insulin-dependent diabetes, particularly in the obese ...